Bismuth Subgallate
CAS 99-26-3
Bismuth Subgallate (CAS 99-26-3) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BISMUTH SUBGALLATE | 19476 | SU | MTHSPL |
| bismuth subgallate | 19476 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Bismuth Subgallate used for in pharmaceutical contexts?
Bismuth Subgallate (CAS 99-26-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Bismuth Subgallate?
No adverse-event association or SIDER side-effect rows are rendered for Bismuth Subgallate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Bismuth Subgallate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Bismuth Subgallate with EU status "restricted".
What clinical phase is Bismuth Subgallate in?
No phase 1-4 clinical development badge is rendered for Bismuth Subgallate because the matched compound identifier rows do not contain a max-phase value.